Trials / Active Not Recruiting
Active Not RecruitingNCT05745883
Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia
A Phase 1b Multicenter, Randomized, Double-Blind, Placebo-Controlled Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DISC-0974 in Participants With Non-Dialysis Dependent Chronic Kidney Disease and Anemia
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Disc Medicine, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 1b study of DISC-0974 will assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult participants with Non-Dialysis Dependent Chronic Kidney Disease and Anemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DISC-0974 | DISC-0974 is administered subcutaneously |
| DRUG | Placebo | Placebo is administered subcutaneously |
Timeline
- Start date
- 2023-04-04
- Primary completion
- 2026-01-01
- Completion
- 2026-05-01
- First posted
- 2023-02-27
- Last updated
- 2025-12-18
Locations
13 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05745883. Inclusion in this directory is not an endorsement.